Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Immutep (IMM) doses its first patient suffering from lung carcinoma as part of its INSIGHT-003 study
  • The patient was treated with the company’s lead product, efti, in combination with an existing approved standard of care treatment
  • The study will continue to recruit up to 20 patients with various solid tumours and first results are expected in calendar year 2022
  • Immutep is trading up two per cent at 51 cents at 11:57 am AEST

Immutep (IMM) has dosed its first patient suffering from lung carcinoma as part of its INSIGHT-003 study.

INSIGHT-003 is a trial conducted by the Institute of Clinical Cancer Research IKF in Frankfurt. The trial will involve patients receiving 30 milligrams of subcutaneous doses of eftilagimod alpha (efti) every two weeks.

The biotechnology company enrolled and dosed the patient – who suffers from metastatic non-small cell lung carcinoma – with pembrolizumab plus doublet chemotherapy combined with Immutep’s lead product candidate, efti.  

The study looks to evaluate a triple combination therapy consisting of efti in conjunction with an existing approved standard of care to assess the treatment’s safety, tolerability and initial efficacy of the combination.

“INSIGHT-003 is the first time a triple combination therapy consisting of efti plus anti-PD-1 plus chemo is administered,” Immutep Chief Strategy Officer and Chief Medical officer Frédéric Triebel said.

“We are evaluating how efti might boost an approved chemotherapy and anti-PD-1 combination therapy, looking at safety and initial activity,” Dr Triebel said.

The study will continue to recruit up to 20 patients with various solid tumours and first results are expected in calendar year 2022.

Immutep was trading up two per cent at 51 cents at 11:57 am AEST.  

IMM by the numbers
More From The Market Herald
The Market Herald Video

" Opthea (ASX:OPT) secures up to US$260m in funding for OPT-302 trials

Opthea (ASX:OPT) secures up to US$170 million in financing and a US$90 million placement to advance…
Creso Pharma (ASX:CPH) -

" Creso Pharma’s (ASX:CPH) ImpACTIVE appoints new brand ambassador

Creso Pharma's (ASX:CPH) subsidiary, ImpACTIVE has appointed multi-sport performance coach Kolby Tullier as brand ambassador.
The Market Herald Video

" Proteomics International (ASX:PIQ) to raise $8m for Promarker development

Proteomics International (ASX:PIQ) receives firm commitments to raise $8 million to advance marketing, sales and further…
The Market Herald Video

" Paradigm Biopharmaceuticals (ASX:PAR) taps investors for $66m to fund future developments

Paradigm Biopharmaceuticals (ASX:PAR) taps investors for $66 million to fund developments into the 2024 calendar year.